Fosun Pharma's (600196.SH) Subsidiary Receives Clinical Trial Approval for HLX37 Injection

Stock News

2025/12/01

Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities (collectively referred to as "Henlius") recently received approval from the National Medical Products Administration for the clinical trial of HLX37 injection (a recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injection) in treating patients with advanced/metastatic solid tumors. Henlius plans to initiate a Phase I clinical trial for HLX37 in China once conditions are met. HLX37 is a self-developed recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody by the group, intended for the treatment of advanced/metastatic solid tumors. Preclinical studies to date have demonstrated HLX37's ability to inhibit tumor growth with favorable safety profiles.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1121426684"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121426684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121426684?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 17:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121426684","market":"sg","top_or_hot":-1,"title":"Fosun Pharma's (600196.SH) Subsidiary Receives Clinical Trial Approval for HLX37 Injection","media":"Stock News","content":"<p>Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities (collectively referred to as \"Henlius\") recently received approval from the National Medical Products Administration for the clinical trial of HLX37 injection (a recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injection) in treating patients with advanced/metastatic solid tumors. Henlius plans to initiate a Phase I clinical trial for HLX37 in China once conditions are met. HLX37 is a self-developed recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody by the group, intended for the treatment of advanced/metastatic solid tumors. Preclinical studies to date have demonstrated HLX37's ability to inhibit tumor growth with favorable safety profiles.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma's (600196.SH) Subsidiary Receives Clinical Trial Approval for HLX37 Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma's (600196.SH) Subsidiary Receives Clinical Trial Approval for HLX37 Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-01 17:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities (collectively referred to as \"Henlius\") recently received approval from the National Medical Products Administration for the clinical trial of HLX37 injection (a recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injection) in treating patients with advanced/metastatic solid tumors. Henlius plans to initiate a Phase I clinical trial for HLX37 in China once conditions are met. HLX37 is a self-developed recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody by the group, intended for the treatment of advanced/metastatic solid tumors. Preclinical studies to date have demonstrated HLX37's ability to inhibit tumor growth with favorable safety profiles.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1121426684","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121426684","pubTimestamp":1764580217,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities (collectively referred to as \"Henlius\") recently received approval from the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK1593":"医美概念股","BK0012":"证金概念","BK0175":"白马股","BK0196":"行业龙头","BK0187":"一线龙头","BK1515":"抗疫概念","BK0060":"抗癌","BK1191":"制药","BK0188":"融资融券","BK0028":"国家队","BK0239":"医药制造","02196":"复星医药","BK0183":"MSCI概念","BK0096":"民营医院"},"translate_title":"复星医药（600196.SH）子公司HLX37注射液获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities (collectively referred to as \"Henlius\") recently received approval from the National Medical Products Administration for the clinical trial of HLX37 injection (a recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injection) in treating patients with advanced/metastatic solid tumors. Henlius plans to initiate a Phase I clinical trial for HLX37 in China once conditions are met. HLX37 is a self-developed recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody by the group, intended for the treatment of advanced/metastatic solid tumors. Preclinical studies to date have demonstrated HLX37's ability to inhibit tumor growth with favorable safety profiles.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}